Papamichael, K., Chachu, K. A., Vajravelu, R. K., Vaughn, B. P., Ni, J., Osterman, M. T., & Cheifetz, A. S. (2017). Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical Gastroenterology and Hepatology, 15(10), 1580-1588.e3. https://doi.org/10.1016/j.cgh.2017.03.031

Papamichael, Konstantinos, Karen A. Chachu, Ravy K. Vajravelu, Byron P. Vaughn, Josephine Ni, Mark T. Osterman, and Adam S. Cheifetz. “Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.” Clinical Gastroenterology and Hepatology 15, no. 10 (October 2017): 1580-1588.e3. https://doi.org/10.1016/j.cgh.2017.03.031.

Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical Gastroenterology and Hepatology. 2017 Oct;15(10):1580-1588.e3.

Papamichael, Konstantinos, et al. “Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.” Clinical Gastroenterology and Hepatology, vol. 15, no. 10, Elsevier BV, Oct. 2017, pp. 1580-1588.e3. Crossref, doi:10.1016/j.cgh.2017.03.031.

Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical Gastroenterology and Hepatology. Elsevier BV; 2017 Oct;15(10):1580-1588.e3.